Literature DB >> 2817158

Person-years of life lost due to cancer in the United States, 1970 and 1984.

J W Horm1, E J Sondik.   

Abstract

The number of deaths due to cancer in the United States reached an all-time high of 453,450 deaths in 1984 and, due to the dynamics of population growth, will continue to increase if the risk of dying from cancer does not change. Between 1970 and 1984, the total Person-Years of Life Lost (PYLL), the sum of the difference between the actual age at death and the expected remaining lifetime for each person who died of cancer, increased for most cancer sites as well as for all sites combined. In 1984, 6,881,281 person-years of life were lost due to cancer deaths, up from 5,303,668 in 1970. The exceptions are those cancers for which there has been major progress in either prevention or treatment; e.g., stomach and cervix uteri (prevention) and testicular, Hodgkin's disease, leukemia, and childhood cancers (treatment). The Average Years of Life Lost (AYLL) per person dying from cancer in 1984 was generally less than in 1970. Overall, each person who died from cancer in 1984 died 15.2 years earlier than his/her life expectancy. The greatest loss was for those who died of childhood cancers (66.9 years earlier), followed by testicular cancer (35.8 years earlier). The least loss relative to the expectation of life was for those who died of prostate cancer. The 25,400 men who died from prostate cancer in 1984 died an average of nine years earlier than otherwise expected.

Entities:  

Mesh:

Year:  1989        PMID: 2817158      PMCID: PMC1349798          DOI: 10.2105/ajph.79.11.1490

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  4 in total

1.  Ten- to fourteen-year effect of screening on breast cancer mortality.

Authors:  S Shapiro; W Venet; P Strax; L Venet; R Roeser
Journal:  J Natl Cancer Inst       Date:  1982-08       Impact factor: 13.506

2.  Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.

Authors:  L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

3.  Papanicolaou smear screening and cervical cancer. What can you expect?

Authors:  B Stenkvist; R Bergström; G Eklund; C H Fox
Journal:  JAMA       Date:  1984-09-21       Impact factor: 56.272

4.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

  4 in total
  10 in total

1.  Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations.

Authors:  Aditya Bagrodia; Costantine Albany; Timothy A Masterson
Journal:  Adv Urol       Date:  2018-08-19

Review 2.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 3.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Prostatic cancer: an overview.

Authors:  J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

5.  Geographical variation in the standardized years of potential life lost ratio (SYPLR) in women dying from malignancies of the breast in England and Wales.

Authors:  P Yuen; J Haybittle; D Machin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Lifespan variation by occupational class: compression or stagnation over time?

Authors:  Alyson A van Raalte; Pekka Martikainen; Mikko Myrskylä
Journal:  Demography       Date:  2014-02

7.  The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.

Authors:  Joseph M Unger; Michael LeBlanc; Charles D Blanke
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

Review 8.  Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.

Authors:  K S Chaudhary; P D Abel; E N Lalani
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

9.  The loss in expectation of life after colon cancer: a population-based study.

Authors:  Therese M-L Andersson; Paul W Dickman; Sandra Eloranta; Annika Sjövall; Mats Lambe; Paul C Lambert
Journal:  BMC Cancer       Date:  2015-05-17       Impact factor: 4.430

10.  Macro Risk: A Versatile and Universal Strategy for Measuring the Overall Safety of Hazardous Industrial Installations in China.

Authors:  Guantao Wang; Jingjing Pei
Journal:  Int J Environ Res Public Health       Date:  2019-05-14       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.